Harnessing the Power of Tumor Gene Therapy to Turn the Tide in the Battle Against Cancer
Akamis Bio is a clinical-stage oncology company whose mission is to leverage its groundbreaking tumor gene therapy platform to positively impact the lives of people living with cancer.
To achieve our mission, we are developing a portfolio of Tumor-Specific Immuno-Gene (T-SIGn®) therapeutics which aim to enable a patient’s own immune system to recognize, attack, and clear their tumor tissue. T-SIGn® therapeutics home specifically to solid tumors following intravenous delivery where they drive expression of therapeutic proteins to remodel the tumor microenvironment and trigger robust antitumor immune responses.
Our T-SIGn® therapeutics are a novel class of medicines with potential for use in the monotherapy setting, as well as in combination with other immuno-oncology agents, to deliver efficacy and offer new hope to people living with difficult-to-treat solid tumors.
A stromal-targeted tumor gene therapy driving intratumoral expression of a FAP-CD3 bispecific antibody, CXCL-9, CXCL-10 & interferon alpha.
Clinical Studies: STAR, NEBULA, MOAT.
A growing pipeline of T-SIGn® therapeutics aiming to enable a patient’s immune system to recognize, attack, and clear solid tumors .
T-SIGn® therapeutics are viral vector based, tumor gene therapies which are capable of homing specifically to primary and metastatic solid tumors following intravenous delivery. Once at the tumor site, T-SIGn® therapeutics can drive intratumoral expression of multiple immunologically active biomolecules and therapeutic proteins to remodel the tumor microenvironment and trigger robust antitumor immune responses.